308.10 -14.25 (-4.42%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
308.0
Today’s High
324.25
52 Week Low
263.45
52 Week High
413.5
309.50 -13.15 (-4.08%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
308.05
Today’s High
324.3
52 Week Low
263.35
52 Week High
413.75
Key Metrics
- Market Cap (In Cr) 2914.26
- Beta 1.04
- Div. Yield (%) 0
- P/B 1.23
- TTM P/E -
- Sector P/E 28.26
- D/E 1.34
- Open Price 322.1
- Prev Close 322.35
Analysis
Price Analysis
-
1 Week-2.03%
-
3 Months12.05%
-
6 Month-4.74%
-
YTD-7.77%
-
1 Year-16.26%
Risk Meter
- 36% Low risk
- 36% Moderate risk
- 36% Balanced Risk
- 36% High risk
- 36% Extreme risk
Recos
4 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 0
- Buy
- 1
- Strong Buy
- 3
Strides Pharma Science News
Strides Pharma shares hit 52-week low, down over 8% on Ranitidine suspension
1 min read . 27 Sep 2019
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 3070.25
- Selling/ General/ Admin Expenses Total
- 1351.7
- Depreciation/ Amortization
- 230.46
- Other Operating Expenses Total
- 19.75
- Total Operating Expense
- 3607.08
- Operating Income
- -536.83
- Net Income Before Taxes
- -652.51
- Net Income
- -460.21
- Diluted Normalized EPS
- -30.4
- Period
- 2022
- Total Assets
- 6975.86
- Total Liabilities
- 4616.63
- Total Equity
- 2359.23
- Tangible Book Valueper Share Common Eq
- 139.03
- Period
- 2022
- Cashfrom Operating Activities
- -257.82
- Cashfrom Investing Activities
- -118.73
- Cashfrom Financing Activities
- 421.32
- Net Changein Cash
- 44.9
- Period
- 2021
- Total Revenue
- 3315.87
- Selling/ General/ Admin Expenses Total
- 1150.49
- Depreciation/ Amortization
- 201.72
- Other Operating Expenses Total
- 12.15
- Total Operating Expense
- 2876.59
- Operating Income
- 439.28
- Net Income Before Taxes
- 275.44
- Net Income
- 268.44
- Diluted Normalized EPS
- 27.05
- Period
- 2021
- Total Assets
- 7015.02
- Total Liabilities
- 4238.36
- Total Equity
- 2776.66
- Tangible Book Valueper Share Common Eq
- 187.06
- Period
- 2021
- Cashfrom Operating Activities
- 481.44
- Cashfrom Investing Activities
- -520.82
- Cashfrom Financing Activities
- -15.8
- Net Changein Cash
- -56.4
- Period
- 2020
- Total Revenue
- 2751.97
- Selling/ General/ Admin Expenses Total
- 907.9
- Depreciation/ Amortization
- 173.7
- Other Operating Expenses Total
- 14.06
- Total Operating Expense
- 2455.48
- Operating Income
- 296.49
- Net Income Before Taxes
- 54.68
- Net Income
- 36.39
- Diluted Normalized EPS
- 12.8
- Period
- 2020
- Total Assets
- 6151.73
- Total Liabilities
- 3624.32
- Total Equity
- 2527.42
- Tangible Book Valueper Share Common Eq
- 173.34
- Period
- 2020
- Cashfrom Operating Activities
- 204.79
- Cashfrom Investing Activities
- 1306.16
- Cashfrom Financing Activities
- -1709.45
- Net Changein Cash
- -183.66
- Period
- 2019
- Total Revenue
- 2178.37
- Selling/ General/ Admin Expenses Total
- 699.8
- Depreciation/ Amortization
- 117.39
- Other Operating Expenses Total
- 9.8
- Total Operating Expense
- 2007.58
- Operating Income
- 170.79
- Net Income Before Taxes
- 62.4
- Net Income
- 324.62
- Diluted Normalized EPS
- 7.62
- Period
- 2019
- Total Assets
- 7979.66
- Total Liabilities
- 5330.95
- Total Equity
- 2648.7
- Tangible Book Valueper Share Common Eq
- -26.53
- Period
- 2019
- Cashfrom Operating Activities
- 60.05
- Cashfrom Investing Activities
- -148.49
- Cashfrom Financing Activities
- 194.27
- Net Changein Cash
- 109.73
- Period
- 2018
- Total Revenue
- 2845.11
- Selling/ General/ Admin Expenses Total
- 919.79
- Depreciation/ Amortization
- 154.04
- Other Operating Expenses Total
- 17.36
- Total Operating Expense
- 2629.75
- Operating Income
- 215.37
- Net Income Before Taxes
- 79.95
- Net Income
- 664.52
- Diluted Normalized EPS
- 9.85
- Period
- 2018
- Total Assets
- 6708.41
- Total Liabilities
- 4244.75
- Total Equity
- 2463.66
- Tangible Book Valueper Share Common Eq
- -8.14
- Period
- 2018
- Cashfrom Operating Activities
- 171.61
- Cashfrom Investing Activities
- 582.59
- Cashfrom Financing Activities
- -1015.69
- Net Changein Cash
- -258.92
- Period
- 2017
- Total Revenue
- 2755.44
- Selling/ General/ Admin Expenses Total
- 823.95
- Depreciation/ Amortization
- 126.15
- Other Operating Expenses Total
- -3.77
- Total Operating Expense
- 2378.35
- Operating Income
- 377.09
- Net Income Before Taxes
- 343.12
- Net Income
- 399.75
- Diluted Normalized EPS
- 28.77
- Period
- 2017
- Total Assets
- 8274.2
- Total Liabilities
- 5520.33
- Total Equity
- 2753.87
- Tangible Book Valueper Share Common Eq
- 8.75
- Period
- 2017
- Cashfrom Operating Activities
- -250.62
- Cashfrom Investing Activities
- -686.69
- Cashfrom Financing Activities
- 338.22
- Net Changein Cash
- -595.66
- Period
- 2022-09-30
- Total Revenue
- 897.1
- Selling/ General/ Admin Expenses Total
- 191.69
- Depreciation/ Amortization
- 61.7
- Other Operating Expenses Total
- 234.15
- Total Operating Expense
- 860.11
- Operating Income
- 36.98
- Net Income Before Taxes
- -38.07
- Net Income
- 22.82
- Diluted Normalized EPS
- -0.58
- Period
- 2022-09-30
- Total Assets
- 6844.86
- Total Liabilities
- 4513.49
- Total Equity
- 2331.37
- Tangible Book Valueper Share Common Eq
- 135.63
- Period
- 2022-09-30
- Cashfrom Operating Activities
- -44.18
- Cashfrom Investing Activities
- -85.49
- Cashfrom Financing Activities
- 69.74
- Net Changein Cash
- -59.86
- Period
- 2022-06-30
- Total Revenue
- 940.07
- Selling/ General/ Admin Expenses Total
- 183.66
- Depreciation/ Amortization
- 60.4
- Other Operating Expenses Total
- 233.62
- Total Operating Expense
- 1015.06
- Operating Income
- -74.98
- Net Income Before Taxes
- -163.4
- Net Income
- -135.89
- Diluted Normalized EPS
- -10.37
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 866.02
- Selling/ General/ Admin Expenses Total
- 157.25
- Depreciation/ Amortization
- 60.68
- Other Operating Expenses Total
- 239.78
- Total Operating Expense
- 962.14
- Operating Income
- -96.12
- Net Income Before Taxes
- -102.52
- Net Income
- 29.22
- Diluted Normalized EPS
- 8.83
- Period
- 2022-03-31
- Total Assets
- 6975.86
- Total Liabilities
- 4616.63
- Total Equity
- 2359.23
- Tangible Book Valueper Share Common Eq
- 139.03
- Period
- 2022-03-31
- Cashfrom Operating Activities
- -257.82
- Cashfrom Investing Activities
- -118.73
- Cashfrom Financing Activities
- 421.32
- Net Changein Cash
- 44.9
- Period
- 2021-12-31
- Total Revenue
- 794.39
- Selling/ General/ Admin Expenses Total
- 179.94
- Depreciation/ Amortization
- 60.9
- Other Operating Expenses Total
- 208.75
- Total Operating Expense
- 866.12
- Operating Income
- -71.72
- Net Income Before Taxes
- -131.14
- Net Income
- -121.67
- Diluted Normalized EPS
- -12.43
- Period
- 2021-12-31
- Period
- 2021-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day326.78
- 10 Day330.08
- 20 Day342.33
- 50 Day346.81
- 100 Day333.6
- 300 Day332.28
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 272.25
- -2.35
- -0.86
- 355.15
- 257
- 3067.28
- Wockhardt
- 197.85
- -6.6
- -3.23
- 386.99
- 201.55
- 2946.03
- Strides Pharma Science
- 308.1
- -14.25
- -4.42
- 413.5
- 263.45
- 2914.26
- Marksans Pharma
- 62.9
- -1.05
- -1.64
- 69.6
- 38.7
- 2897.98
- Shilpa Medicare
- 241.1
- -6.3
- -2.55
- 547.9
- 246
- 2148.35
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 25.84
- 2.79
- 15.57
- 26.97
- Wockhardt
- -
- 0.77
- -10.45
- -10.27
- Strides Pharma Science
- -
- 1.23
- -0.14
- -0.17
- Marksans Pharma
- 14.18
- 2.18
- 19.29
- 11.2
- Shilpa Medicare
- 36.66
- 1.18
- 8.96
- 12.81
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 69.11%
- 62,405,441
- Others
- 18.87%
- 17,036,540
- ROUTE ONE OFFSHORE MASTER FUND, L.P.
- 4.6%
- 4,156,616
- ROUTE ONE FUND I, L.P.
- 2.79%
- 2,518,430
- BNP PARIBAS ARBITRAGE
- 1.33%
- 1,204,714
- Others
- 9.19%
- 8,295,669
- ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C
- 6.29%
- 5,679,955
- QUANT MUTUAL FUND - QUANT FLEXI CAP FUND
- 3.12%
- 2,815,969
- SBI LONG TERM EQUITY FUND
- 2.24%
- 2,024,798
- Others
- 0%
- 607
- LIFE INSURANCE CORPORATION OF INDIA
- 4.94%
- 4,459,806
- Others
- 0.31%
- 290,247
- CAPRI GLOBAL ADVISORY SERVICES PVT LTD
- 1.33%
- 1,200,000
- Others
- 3.5%
- 3,157,609
- Others
- 3.56%
- 3,215,158
- SATPAL KHATTAR
- 1.73%
- 1,560,032
- Others
- 0.89%
- 804,171
- OMAN INDIA JOINT INVESTMENT FUND II
- 1.12%
- 1,011,103
- Others
- 0.39%
- 361,635
- Others
- 1.17%
- 1,060,895
- Others
- 1.02%
- 921,117
- Others
- 0.39%
- 350,391
- Others
- 0.11%
- 101,084
- Others
- 0.06%
- 49,732
- Others
- 0.05%
- 48,392
- Others
- 0.03%
- 25,000
- Others
- 0.02%
- 21,000
- Others
- 0.01%
- 12,525
- Others
- 0.01%
- 9,025
- Others
- 0.01%
- 8,125
- Others
- 0.01%
- 5,096
- Promoter & Promoter Group Shareholding
- 30.89%
- 27,897,263
- PRONOMZ VENTURES LLP
- 18.45%
- 16,662,647
- KARUNA BUSINESS SOLUTIONS LLP
- 1.86%
- 1,677,540
- SHASUN LEASING AND FINANCE (P) LIMITED
- 1.11%
- 1,005,000
- SHASUN ENTERPRISES LLP (FORMERLY, DEVENDRA ESTATES LLP)
- 0.91%
- 823,953
- AMBEMATA SECURITIES
- 0.53%
- 481,660
- AGRAGANYA PRIVATE TRUST (Trustee: BARCLAYS WEALTH TRUSTEES (I) PVT LTD)
- 0.33%
- 300,000
- ABUSHA INVESTMENT & MANANGEMENT SERVICES LLP
- 0.2%
- 181,216
- ARUN KUMAR PILLAI
- 2.04%
- 1,840,997
- K R RAVISHANKAR
- 1.39%
- 1,255,593
- NITIN KUMAR V
- 0.58%
- 527,093
- JATIN V
- 0.51%
- 461,042
- LEELA V
- 0.46%
- 417,867
- VIMAL KUMAR S
- 0.32%
- 293,201
- RUPALI JATIN
- 0.21%
- 189,826
- PADMAKUMAR KARUNAKARAN PILLAI
- 0.21%
- 186,485
- SAJJAN D
- 0.2%
- 176,670
- MONISHA NITIN
- 0.17%
- 149,764
- K R LAKSHMI
- 0.14%
- 130,365
- VIMAL KUMAR S - (HUF)
- 0.13%
- 115,158
- SAJITHA PILLAI
- 0.11%
- 95,000
- POOJA SRISRIMAL
- 0.1%
- 93,750
- SUCHI CHAITANYA SRISRIMAL
- 0.1%
- 93,750
- S ABHAYA KUMAR HUF
- 0.09%
- 78,035
- HEMALATHA PILLAI
- 0.07%
- 66,760
- RAJITHA GOPALAKRISHNAN
- 0.07%
- 60,000
- CHAITANYA D
- 0.07%
- 59,882
- ABHAYA KUMAR S
- 0.06%
- 57,869
- PURUSHOTHAMAN PILLAI G
- 0.04%
- 33,013
- GAYATRI NAIR
- 0.04%
- 33,000
- ADITYA ARUN KUMAR
- 0.03%
- 29,922
- JITESH D
- 0.03%
- 25,825
- RAHUL NAIR
- 0.02%
- 20,000
- TARU MARDIA
- 0.02%
- 14,000
- VIBHA SRISRIMAL
- 0.02%
- 14,000
- ANURADHA K R
- 0.01%
- 5,470
- V. NITIN KUMAR (HUF)
- 0%
- 500
- V. JATIN (HUF)
- 0%
- 408
- DEVENDRA KUMAR S
- 0%
- 2
- VINEETHA MOHANAKUMAR PILLAI
- 0.21%
- 190,000
- LAKSHMI GOPALAKRISHNAN
- 0.06%
- 50,000
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 24-Jan-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- 25-Jul-22
- Others
- 24-May-22
- Audited Results & Dividend
- 10-Feb-22
- Quarterly Results & Others
- 28-Jan-22
- Quarterly Results
- 10-Nov-21
- Quarterly Results
- 06-Aug-21
- Quarterly Results
- 27-May-21
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 07-Apr-22
- 17-Feb-22
- EGM
- 03-Sept-21
- 26-Jul-21
- AGM
- 13-Jun-21
- 12-May-21
- POM
- 17-Mar-21
- 10-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-21
- 06-Aug-21
- 05-Aug-21
- 2.5
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Strides Pharma Science
- Industry Biotechnology & Drugs
- ISIN INE939A01011
- BSE Code 532531
- NSE Code STAR
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on development and manufacture of IP-led niche and pharmaceutical products. It operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
MANAGEMENT
- Arun Kumar Executive Chairperson of the Board, Managing Director
- Badree Komandur Group Chief Executive Officer, Executive Director - Finance
- Christoph Funke Chief Operating Officer
- Tanaya Mishra Chief Human Resource Officer
- Anjani Kumar Chief Information Officer
- Raviraj Pillai Chief Scientific Officer
- Manjula Ramamurthy Compliance Officer, Company Secretary
- Sormistha Ghosh Chief Risk Officer, Group General Counsel
- Umesh Kale Chief Quality Officer
Company Summary
STRIDES PHARMA SCIENCE SUMMARY
Strides Pharma Science is trading 4.42% lower at Rs 308.10 as compared to its last closing price. Strides Pharma Science has been trading in the price range of 324.25 & 308.0. Strides Pharma Science has given -7.77% in this year & -2.03% in the last 5 days.
There are 4 analysts who have initiated coverage on Strides Pharma Science. There are 3 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 22.82 Crores in its last quarter.
Listed peers of Strides Pharma Science include Advanced Enzyme Technologies (-0.86%), Wockhardt (-3.23%), Strides Pharma Science (-4.42%) etc.
Strides Pharma Science has a 30.89% promoter holding & 69.11% public holding.
FAQs about Strides Pharma Science
Strides Pharma Science is trading at 308.10 as on 27 Jan, 2023 3:29:38 PM. This is -4.42% lower as compared to its previous closing price of 322.35
The market capitalization of Strides Pharma Science is 2914.26 Cr as on 27 Jan, 2023 3:29:38 PM.
The average broker rating on Strides Pharma Science is Strong Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 0 analysts have given a hold rating
- 1 analysts have given a buy rating
- 3 analysts have given a strong buy rating
The 52 wk high for Strides Pharma Science is 413.5 whereas the 52 wk low is 263.45
Strides Pharma Science can be analyzed on the following key metrics -
- TTM P/E: -
- Sector P/E: 28.26
- Dividend Yield: 0%
- D/E ratio: -
Strides Pharma Science reported a net profit of -460.21 Cr in 2022.
